Latest press releases
Uncovering world’s first structural clues to inhibiting an emerging DNA Damage Response target area for future anti-cancer therapy
Collaborative team from AstraZeneca, University of Sheffield and Pelago BioSciences publish the co-crystal structure of flap endonuclease 1 (FEN1) bound with small molecule inhibitors in Nature Chemical Biology and describe how its function can be inhibited to provide clues for future drug discovery.
Meet Chris Rhodes, a renowned leader in the field of diabetes and obesity research
"I grew up in an artistic musical family, which instilled in me very early on the essence of creativity. Science requires original thinking, and cultivating and using that creativity is fundamental to innovation and momentous discovery".
AstraZeneca’s ambitions for personalised healthcare go far beyond treating cancer
At AstraZeneca, personalised healthcare is about matching medicines to the patients most likely to benefit from them. The approach involves a detailed understanding of the biology of a disease, identifying biomarkers and developing tests, known as companion diagnostics, which doctors can use to identify who is most likely to respond to treatment with a targeted therapy.
New study published in ‘Cancer Cell’ furthers understanding role of CXCR2 in pancreatic cancer
Scientists from AstraZeneca’s Oncology Innovative Medicines Unit, in collaboration with Dr. Jen Morton and Professor Owen Sansom of the Beatson Institute for Cancer Research in Glasgow, have shown how an experimental drug breaks down pancreatic cancers defences, allowing immune cells to attack the tumour. The new study, published in Cancer Cell, discovered that a protein called CXCR2 acts as a guard for the tumour, controlling how the immune system responds to pancreatic cancer.
Clinical trial data unveil a driver of FGFR inhibitor response in gastric cancer - collaborative study published in the journal Cancer Discovery
Scientists from AstraZeneca’s Oncology Innovative Medicines Unit, the Institute of Cancer Research, London and the Royal Marsden Foundation Trust, recently published the results of a clinical biomarker study in solid tumours. The publication defines a potential driver for clinical responses to fibroblast growth factor receptor inhibitors in gastric cancers.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Page Atlas ID: 970733.011
Date of next review: April 2017